Publications by authors named "Danielle S Wallace"
Article Synopsis
- * New treatment options are emerging; however, determining which are safe and effective for older patients, especially in cases of relapse, remains complicated and requires careful assessments.
- * The article outlines strategies for managing older adults with relapsed DLBCL, including advanced therapies like CAR-T cell therapy and other innovative treatments tailored for this age group.
Article Synopsis
- Primary large B-cell lymphomas (IP-LBCLs) occur in "immune-privileged" areas like the CNS, vitreoretina, and testes, where the immune response is weaker.
- These lymphomas typically have a poor prognosis with high chances of returning either at the same spot or another similar site.
- The case discussed features a man with two separate cases of LBCL in the CNS and testis, diagnosed over ten years apart, that were not genetically linked, indicating they were not the same type of cancer.
Many patients with chronic lymphocytic leukemia (CLL) will develop treatment resistance to Bruton tyrosine kinase (BTK) inhibitors. Phosphatidylinositol-3-kinase (PI3K) inhibitors, including umbralisib, have significant clinical activity in relapsed/refractory CLL, but prolonged exposure is associated with potential toxicities. Owing to the synergistic antitumor effects of combined PI3K and BCL-2 inhibition, we sought to explore the feasibility of response-adapted, time-limited therapy to optimize disease control while mitigating the risks of prolonged treatment.
View Article and Find Full Text PDFMonoclonal antibody induced infusion reactions (IRs) can be serious and even fatal. We used clinical data and blood samples from 37 treatment naïve patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) initiating therapy for progressive disease with a single 50 mg dose of intravenous (IV) rituximab at 25 mg/h. Twenty-four (65 %) patients had IRs at a median of 78 min (range 35-128) and rituximab dose of 32 mg (range 15-50).
View Article and Find Full Text PDFBruton tyrosine kinase inhibitors are an effective therapeutic agent for previously untreated patients with chronic lymphocytic leukemia but require indefinite treatment that can result in cumulative toxicities. Novel combinations of agents that provide deep remissions could allow for fixed duration therapy. Acalabrutinib, unlike ibrutinib, does not inhibit anti-CD20 monoclonal antibody-dependent cellular phagocytosis, making it a suitable partner drug to rituximab.
View Article and Find Full Text PDFFamily and migration studies suggest a genetic risk of developing chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL). We hypothesized that CLL patients have an increased risk of additional clonally unrelated B-cell malignancies. To test this, we studied 467 CLL patients (2743 person-years (PYs)) at a single institution over 17 years.
View Article and Find Full Text PDF